NLRP3 and Alzheimer disease: Given the association between T2DM in midlife and later cognitive decline, and in line with evidence demonstrating heightened PBMC NLRP3 immune responses in both T2DM and AD, we examined whether PBMC inflammatory responses to stimulation with Aβ-42 and other NLRP3 agonists were altered in midlife T2DM.